iShares Nasdaq Biotechnology Index Fund (IBB) Rating Reduced by Vetr To Keep – Insider Tradings

IShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) was lowered by investment analysts at crowd sourced stock rating company Vetr from a buy recommendation to a hold recommendation in a research note released to investors and clients on early Mon, Jun 5th. Firm has a $307.00 PT on the financial services providers shares. Vetrs target price points a possible drop of 1.25% from the firms prior close.

IShares Nasdaq Biotechnology Index Fund (IBB) transacted up 1.443% through out intraday market trading on early Mon, topping $315.375. 899,883 stocks of the shares transacted hands. Companys 50 Day SMA is $293.14 and its 200 SMA is $286.87. iShares Nasdaq Biotechnology Index Fund has a 1 year low of $240.30 has a 1 year high of $316.00.

On the other hand, Credit Suisse Group boosted iShares Nasdaq Biotechnology Index Fund from a market weight recommendation to an overweight recommendation in a study on Tue, Mar 21st. The move was based on the current stock valulation.

Most recently the business also announced a periodic dividend, expected to be paid on early Fri, Jun 30th. Investors with a record date on Early Thur, Jun 29th will be given a $0.1768 dividend. The ex-dividend date of this dividend is Tue, Jun 27th. this indicates a $0.71 dividend on a yearly basis and a payout of of 0.23%.

Quite a few investment firms and many large funds have acquired or sold some of the position in IBB. Morgan Stanley upped its stake in iShares Nasdaq Biotechnology Index Fund by 16.3% in the Q1. Morgan Stanley has an ownership of 1,774,505 stocks of the financial services providers shares valued $520,408,000 after scooping up an extra 248,914 shares through out the quarter. JPMorgan Chase boosted its position in stocks of iShares Nasdaq Biotechnology Index Fund by 45.7% in the Q1. JPMorgan Chase has an ownership of 782,179 stocks of the financial services providers shares valued at $229,389,000 after scooping up an extra 245,458 shares through out the quarter. Alliancebernstein boosted its position in stocks of iShares Nasdaq Biotechnology Index Fund by 40.9% in the Q1. Alliancebernstein has an ownership of 481,442 stocks of the financial services providers shares valued at $141,192,000 after scooping up an extra 139,657 shares through out the quarter. PNC Financial Services Group boosted its position in stocks of iShares Nasdaq Biotechnology Index Fund by 1.0% in the Q1. PNC Financial Services Group has an ownership of 210,978 stocks of the financial services providers shares valued at $61,872,000 after scooping up an extra 2,112 shares through out the quarter. Lastly, Janney Capital Management boosted its position in stocks of iShares Nasdaq Biotechnology Index Fund by 34.6% in the Q1. Janney Capital Management has an ownership of 110,807 stocks of the financial services providers shares valued at $32,496,000 after scooping up an extra 28,503 shares through out the quarter. hedge fund investors and investment firms has an ownership of 69.06% of the firms stock.

About iShares Nasdaq Biotechnology Index Fund

IShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment data that correspond generally to the price and pay out performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Continued here:
iShares Nasdaq Biotechnology Index Fund (IBB) Rating Reduced by Vetr To Keep - Insider Tradings